71.74
+3.12%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Exelixis
From its filings with the US Securities and Exchange Commission
Exelixis is based in Alameda, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker EXEL. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 2 January 2026, it reported revenue of $2.32bn and net income of $782.6m. At that date it held total assets of $2.84bn and shareholders' equity of $2.16bn. By region, U.S. accounted for 92.3%, followed by Europe at 6.6% and Japan at 1.1%.
Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and regimens at the forefront of cancer care. We have produced four marketed pharmaceutical products, two of which are formulations of our flagship molecule, cabozantinib, and we are steadily advancing and evolving our product pipeline portfolio, including our lead clinical asset, zanzalintinib, currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of certain forms of colorectal cancer (CRC), as well as the focus of an extensive late-stage clinical development program in other indications. With a rational and disciplined approach to investment, we are leveraging our internal experience and expertise and the strength of strategic partnerships, to identify and pursue opportunities across the landscape of scientific modalities, including small molecules and biotherapeutics, such as antibody-drug conjugates (ADCs).
Quoted from its 10-K, filed 10 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 11 Apr 2000
- Employees
- 1,077
- Website
- exelixis.com ↗
- Head office
- 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Stelios PapadopoulosIndependent Chairman of the Board, Co-Founder$542,596
- Dr. Michael MorrisseyPresident, Chief Executive Officer, Director, since 2000$12.7m
- Mr. Christopher SennerChief Financial Officer, Executive Vice President$4.7m
- Mr. Jeffrey HessekielExecutive Vice President$3.7m
- Dr. Dana AftabExecutive Vice President - Research and Development$3.6m
- Mr. Patrick HaleyExecutive Vice President - Commercial$4.7m
- Dr. Brenda HeftiGeneral Counsel
- Dr. Mary BeckerleIndependent Director$1.2m
- Dr. S. Gail EckhardtIndependent Director$1.2m
- Dr. Maria FreireIndependent Director$511,596
- Mr. Tomas HeymanIndependent Director$499,096
- Mr. David JohnsonIndependent Director$493,907
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 78
- Environment
- 53
- Social
- 99
- Governance
- 81
- Women in the workforce
- 51%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong product portfolio: Exelixis Inc offers a diverse range of innovative pharmaceutical products, giving the company a competitive edge in the market.
- Robust research and development (R&D) capabilities: The company has invested heavily in R&D, allowing them to continuously develop new and improved drugs.
- Established reputation: Exelixis Inc has built a solid reputation for delivering high-quality products and has gained the trust of healthcare professionals worldwide.
Weaknesses
- Reliance on key products: The company's revenue heavily relies on a few key products, which could pose a risk if sales decline or face regulatory issues.
- Limited geographic presence: Exelixis Inc primarily operates in select markets, limiting its potential customer base and growth opportunities.
- Vulnerability to market competition: Intense competition from rival pharmaceutical companies could impact market share and profitability.
Opportunities
- Expansion into new markets: Exelixis Inc can explore untapped markets or enter into strategic partnerships to reach a wider customer base.
- Growing demand for innovative therapies: With rising healthcare needs and advancements in medical science, there is an increasing demand for new and effective treatments.
- Emerging markets: The company can take advantage of opportunities offered by emerging markets, where healthcare infrastructure and access to medicines are improving.
Threats
- Stringent regulatory environment: Regulatory changes or delays in obtaining approvals may impact the company's ability to launch new products or expand into new markets.
- Intellectual property challenges: Exelixis Inc may face patent infringements or challenges, potentially affecting the exclusivity and profitability of its products.
- Economic uncertainties: Global economic fluctuations, healthcare reforms, or changes in insurance coverage could impact consumer spending on pharmaceuticals.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.